JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB275842

Human UCHL5 knockout HEK-293 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

UCHL5 KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control available. Knockout achieved by CRISPR/Cas9 X = 2 bp deletion Frameshift: 98.27%. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.

View Alternative Names

AD-019, CGI 70, INO80 complex subunit R, INO80R, UCHL5_HUMAN, Ubiquitin C terminal hydrolase L5, Ubiquitin C-terminal hydrolase UCH37, Ubiquitin carboxyl terminal esterase L5, Ubiquitin carboxyl terminal hydrolase L5, Ubiquitin carboxyl-terminal hydrolase isozyme L5, Ubiquitin thioesterase L5, Ubiquitin thiolesterase L5

1 Images
Next Generation Sequencing - Human UCHL5 knockout HEK-293 cell line (AB275842)
  • NGS

Supplier Data

Next Generation Sequencing - Human UCHL5 knockout HEK-293 cell line (AB275842)

Knockout achieved by CRISPR/Cas9; X = 2 bp deletion; Frameshift : 98.27%

Key facts

Cell type

HEK-293

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Next Generation Sequencing

Mutation description

Knockout achieved by CRISPR/Cas9 X = 2 bp deletion Frameshift: 98.27%

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "NGS": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab275842-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab259776 Human wild-type HEK-293 cell line", "number":"AB275842-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab275842 Human UCHL5 knockout HEK-293 cell line", "number":"AB275842-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab275842-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab275842 Human UCHL5 knockout HEK-293 cell line", "number":"AB275842-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
UCHL5
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Next Generation Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
-196°C|-80°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

UCH37 also known as ubiquitin carboxyl-terminal hydrolase L5 (UCHL5) is a deubiquitinating enzyme of approximately 37 kDa mass. This protein functions by cleaving ubiquitin moieties from polyubiquitin chains facilitating protein degradation or recycling processes. UCH37 expression is observed in various tissues with higher expression noted in the liver and kidney indicating its significant cellular roles in these organs.
Biological function summary

UCH37 plays a role in the ubiquitin-proteasome system where it is an integral component of the 19S regulatory particle of the 26S proteasome complex. Through this association UCH37 participates in the removal of ubiquitin from substrates targeted for proteasomal degradation. This action regulates protein turnover and prevents unnecessary degradation of proteins which is important for maintaining cell homeostasis and controlling protein quality.

Pathways

The modulation of proteostasis by UCH37 directly influences the ubiquitin-proteasome pathway and the associated cellular stress responses. Its activity can impact the NF-kappaB signaling pathway by regulating the stability of components within this pathway interacting with other proteins such as the proteasome subunit RPN13 and proteasome-associated DUBs. The precise regulation of protein levels within these pathways ensures that cells respond appropriately to stress and inflammation.

Abnormal regulation or expression of UCH37 contributes to several pathological conditions. Cancer and neurodegenerative disorders are two prominent examples in which UCH37 plays a role. Elevated levels or dysfunctional UCH37 activity can disrupt proteostasis leading to uncontrolled cell proliferation or cell death resistance in cancer or the accumulation of misfolded proteins in conditions like Alzheimer's disease. Additionally interactions of UCH37 with oncogenic proteins or tau proteins in neurodegenerative conditions reflect its relevance in the progression of these diseases.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com